Sunday, 22 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
New Paper Alert

CheckMate 227: nivolumab plus ipilimumab gives higher 7-year survival than chemotherapy in NSCLC

Final 7.5-year results show 7-year overall survival of 19% versus 10% in PD-L1-positive disease, and 14% versus 4% in PD-L1-negative disease, Stephen V Liu reported.

“In PD-L1+, 7y OS 19% with nivo/ipi vs 10% with chemo with rates of ongoing response 25% vs 3%.”— Stephen V Liu, MD

Final 7.5-year outcomes from the CheckMate 227 trial of first-line nivolumab plus ipilimumab in non-small cell lung cancer (NSCLC) have been published in JTO, according to a post on X by thoracic oncologist Stephen V Liu.

In patients with PD-L1-positive disease, Liu wrote, 7-year overall survival (OS) was 19% with nivolumab and ipilimumab, compared with 10% with chemotherapy. Rates of ongoing response were 25% with the immunotherapy combination versus 3% with chemotherapy.

In PD-L1-negative disease, 7-year OS was 14% with nivolumab and ipilimumab versus 4% with chemotherapy. Ongoing responses were reported in 20% of patients on the combination versus 3% on chemotherapy.

Liu is Chief of Hematology and Oncology at Georgetown and MedStar Georgetown University Hospital, according to his profile.

Original source

#lung-cancer#trial#therapeutics

Related stories

More in New Paper Alert

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.